Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Applied Genetic Technologies Corporation, a clinical stage biotechnology company developing human therapeutics, has closed on an $11.8 million financing round led by InterWest Partners of Menlo Park, California. Other participants in the round included Intersouth Partners and MedImmune Ventures.
Subscribe to our email newsletter
The investment funds will be used by Applied Genetic Technologies Corporation (AGTC) to complete the next phase in human clinical trials for its gene therapy treatments for alpha-1 antitrypsin deficiency (alpha-1), a form of emphysema, and Lebers congenital amaurosis, a form of childhood blindness, and preclinical development of gene therapy treatment for achromatopsia, a form of daytime blindness.
Sue Washer, president and CEO of AGTC, said: “We are delighted to have the support of such esteemed investors to advance our novel products through development. The clinical results stemming from the delivery of genes to correct inherited disorders are promising, especially for patients with genetic ocular diseases for which no treatment options are currently available.”